Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What sector does Apnimed, Inc. Common Stock (APMD) operate in?
Apnimed, Inc. Common Stock belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Apnimed, Inc. Common Stock (APMD) current stock price?
As of the latest data, Apnimed, Inc. Common Stock stock price is $18.95, with a previous close of $18.99. Apnimed, Inc. Common Stock lost -$0.04 in the last trading session, representing a -0.21% loss.
What is Apnimed, Inc. Common Stock (APMD) current market capitalization?
Apnimed, Inc. Common Stock market cap is approximately 788.90 million.
What is Apnimed, Inc. Common Stock (APMD) Earnings Per Share (EPS)?
The trailing EPS is $7.22, and the forward EPS is -$3.98.
What is Apnimed, Inc. Common Stock (APMD) Price-to-Earnings (P/E) ratio?
Apnimed, Inc. Common Stock current P/E ratio is 2.62.
What is Apnimed, Inc. Common Stock (APMD) EBITDA?
Apnimed, Inc. Common Stock EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -11.70 million.
Does Apnimed, Inc. Common Stock (APMD) pay dividends?
No. Apnimed, Inc. Common Stock does not pay a dividend.
What is Apnimed, Inc. Common Stock (APMD) beta (volatility) score?
Apnimed, Inc. Common Stock has a beta of 0.004, indicating lower volatility than the overall market.